Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Kenta Haraya"'
Autor:
Hikaru Koga, Takashi Yamano, Juan Betancur, Satoko Nagatomo, Yousuke Ikeda, Kazuki Yamaguchi, Yoshiaki Nabuchi, Kazuki Sato, Yuri Teranishi-Ikawa, Motohiko Sato, Hiroyuki Hirayama, Akira Hayasaka, Takuya Torizawa, Kenta Haraya, Zenjiro Sampei, Hirotake Shiraiwa, Takehisa Kitazawa, Tomoyuki Igawa, Taichi Kuramochi
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTEfficient production of bispecific antibodies (BsAbs) in single mammalian cells is essential for basic research and industrial manufacturing. However, preventing unwanted pairing of heavy chains (HCs) and light chains (LCs) is a challenging t
Externí odkaz:
https://doaj.org/article/281415e66ed346d99393535f365215ff
Autor:
Chisato Kaneko, Haruka Tsutsui, Kazuhisa Ozeki, Masaki Honda, Kenta Haraya, Yoshinori Narita, Mika Kamata-Sakurai, Junichi Kikuta, Mitsuyasu Tabo, Masaru Ishii
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract STA551, a novel anti-CD137 switch antibody, binds to CD137 in an extracellular ATP concentration-dependent manner. Although STA551 is assumed to show higher target binding in tumor tissues than in normal tissues, quantitative detection of th
Externí odkaz:
https://doaj.org/article/c4d3885a5dc747a18ef3d9f7eaccf9fa
Autor:
Yuji Hori, Ken Ohmine, Hitoshi Katada, Yuki Noguchi, Kazuki Sato, Takeru Nambu, Lam Runyi Adeline, Gan Siok Wan, Kenta Haraya, Kazuhisa Ozeki, Masahiko Nanami, Tatsuhiko Tachibana, Zenjiro Sampei, Taichi Kuramochi, Junichi Nezu, Kunihiro Hattori, Tomoyuki Igawa
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen–antibo
Externí odkaz:
https://doaj.org/article/664a7d33da584019aead7576585d2286
Autor:
Hiroyasu Muramatsu, Taichi Kuramochi, Hitoshi Katada, Atsunori Ueyama, Yoshinao Ruike, Ken Ohmine, Meiri Shida-Kawazoe, Rie Miyano-Nishizawa, Yuichiro Shimizu, Momoko Okuda, Yuji Hori, Madoka Hayashi, Kenta Haraya, Nobuhiro Ban, Tatsuya Nonaka, Masaki Honda, Hidetomo Kitamura, Kunihiro Hattori, Takehisa Kitazawa, Tomoyuki Igawa, Yoshiki Kawabe, Junichi Nezu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
Abstract Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeuti
Externí odkaz:
https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c
Publikováno v:
Pharmaceuticals, Vol 15, Iss 5, p 508 (2022)
Therapeutic monoclonal antibodies (mAbs) have been a promising therapeutic approach for several diseases and a wide variety of mAbs are being evaluated in clinical trials. To accelerate clinical development and improve the probability of success, pha
Externí odkaz:
https://doaj.org/article/df203e4d65ad459ea3bf350d1e9f8b11
Autor:
Taku Fukuzawa, Zenjiro Sampei, Kenta Haraya, Yoshinao Ruike, Meiri Shida-Kawazoe, Yuichiro Shimizu, Siok Wan Gan, Machiko Irie, Yoshinori Tsuboi, Hitoshi Tai, Tetsushi Sakiyama, Akihisa Sakamoto, Shinya Ishii, Atsuhiko Maeda, Yuki Iwayanagi, Norihito Shibahara, Mitsuko Shibuya, Genki Nakamura, Takeru Nambu, Akira Hayasaka, Futa Mimoto, Yuu Okura, Yuji Hori, Kiyoshi Habu, Manabu Wada, Takaaki Miura, Tatsuhiko Tachibana, Kiyofumi Honda, Hiroyuki Tsunoda, Takehisa Kitazawa, Yoshiki Kawabe, Tomoyuki Igawa, Kunihiro Hattori, Junichi Nezu
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract Dysregulation of the complement system is linked to the pathogenesis of a variety of hematological disorders. Eculizumab, an anti-complement C5 monoclonal antibody, is the current standard of care for paroxysmal nocturnal hemoglobinuria (PNH
Externí odkaz:
https://doaj.org/article/84b20be1cd2e48b4b4a92b1de12240c0
Autor:
Zenjiro Sampei, Kenta Haraya, Tatsuhiko Tachibana, Taku Fukuzawa, Meiri Shida-Kawazoe, Siok Wan Gan, Yuichiro Shimizu, Yoshinao Ruike, Shu Feng, Taichi Kuramochi, Masaru Muraoka, Takehisa Kitazawa, Yoshiki Kawabe, Tomoyuki Igawa, Kunihiro Hattori, Junichi Nezu
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0209509 (2018)
Modulating the complement system is a promising strategy in drug discovery for disorders with uncontrolled complement activation. Although some of these disorders can be effectively treated with an antibody that inhibits complement C5, the high plasm
Externí odkaz:
https://doaj.org/article/a2d17433f8f441739254a843d52c862a
Autor:
Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, Futa Mimoto, Yoshinobu Higuchi, Shinya Ishii, Shigero Tamba, Naoka Hironiwa, Kozue Nagano, Tetsuya Wakabayashi, Hiroyuki Tsunoda, Kunihiro Hattori
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63236 (2013)
Monoclonal antibodies are widely used to target disease-related antigens. However, because conventional antibody binds to the antigen but cannot eliminate the antigen from plasma, and rather increases the plasma antigen concentration by reducing the
Externí odkaz:
https://doaj.org/article/5e72165db2b0430682a83824010d9f36
Autor:
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tatsuhiko Tachibana, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi, Kunihiro Hattori
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57479 (2013)
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors). To overcome these drawbacks, we screened asymmetric bisp
Externí odkaz:
https://doaj.org/article/9f57fabaafda4b53b4d59a5865060934
Autor:
Kenta Haraya, Tatsuhiko Tachibana
Publikováno v:
BioDrugs. 37:99-108
Recently, increasing FcRn binding by Fc engineering has become a promising approach for prolonging the half-life of therapeutic monoclonal antibodies (mAbs). This study is the first to investigate the optimization of an allometric scaling approach fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5203e0cd6eed9d84a5bc90300e5dc346
https://doi.org/10.1007/s40259-022-00566-2
https://doi.org/10.1007/s40259-022-00566-2